A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Condition:   B-Cell Non-Hodgkin Lymphoma Interventions:   Drug: Epcoritamab;   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Lenalidomide Sponsors:   AbbVie;   Genmab Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials